An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO

NCT00379795 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

853

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Neovascularization, Age-related Macular Degeneration

Interventions

DRUG: Ranibizumab 0.5 mg

Sponsor

Genentech, Inc.